The United Kingdom and the United States have signed a key commercial pact that will guarantee zero tariffs on UK pharmaceutical products going into the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has pledged to boost spending on pharmaceuticals through the public health system. This move ensures that import taxes on these crucial goods will remain at zero for a period of three years.
This agreement follows earlier statements to hike duties on branded pharmaceutical imports, with increases mentioned reaching one hundred percent.
"This arrangement with the UK reinforces the international landscape for new treatments and introduces long-overdue balance to U.S.–U.K. drug exports," a release noted.
Trade Impact
Pharmaceuticals constitute one of the UK's biggest exports to the United States, which is clearly the biggest destination for large companies like GSK and AstraZeneca.
Trade data indicate that in the 12 months to the end of last September, the UK sold medicines totaling £11.1bn to the US. This value made up 17.4% of all goods exports in that timeframe.
"This guarantee safeguards employment, increases funding and sets the stage for the UK to become a global hub for life sciences," a minister remarked.
Key UK Commitments
The agreement entails several specific pledges from the UK:
- Price Threshold Increase: The UK will raise the price threshold at which it deems new medicines to be unaffordable by a quarter.
- Higher Drug Budget: There is a goal to raise total public funding on treatments from 0.3% of the national economy to 0.6 percent over the next decade.
- Refund Ceiling: The amount pharmaceutical firms must pay back to the NHS to control costs will be restricted at 15%. Previously, refunds exceeded twenty percent.
Industry Background
The pact takes place against a long-running dispute between the pharmaceutical industry and the UK government over medicine costs and NHS adoption.
These tensions were intensified by arguments that US consumers were charged a premium for the identical medicines than patients in the Britain and the EU.
Recently, several large pharmaceutical investments in the UK have been halted or scrapped, while multi-billion-dollar investments have been pledged toward US facilities.
One official publicly accepted that the NHS must invest a greater share on drugs, noting that its spending on drugs had decreased as a share of its total funding over the previous ten-year period.
